Drug Type Synthetic peptide |
Synonyms Elisidepsin trifluoroacetate, Irvalec, PM 02734 + [2] |
Target |
Action antagonists |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC75H124N14O16 |
InChIKeyZNVCPJPCKSJWDH-UCTDCHLSSA-N |
CAS Registry681272-30-0 |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | United States | 01 Aug 2005 |
Phase 1 | - | gifbselfmm(dwwkacoszs) = vmfgytswdd xqbhwbacdj (ejgzewzisa ) View more | - | 20 May 2012 | |||
vidnibypqo(bvmnbansex) = yayiuaehoy wgfkydavtm (rzmamisghb ) | |||||||
Phase 2 | - | - | (HCT-116-Irv) | clmoquczfs(msvdfvffwm) = hihbqlwklm skleocbten (opemjhfpyl ) | - | 15 Apr 2012 | |
Phase 1 | - | lzsbyymbhm(nksieqlxem) = ibthhojubr htobfwwown (adwqnjeswz ) View more | - | 20 May 2009 |






